-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Comparison: LadRx (OTCMKTS:CYTR) Vs. Quince Therapeutics (NASDAQ:QNCX)
Critical Comparison: LadRx (OTCMKTS:CYTR) Vs. Quince Therapeutics (NASDAQ:QNCX)
LadRx (OTCMKTS:CYTR – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
Analyst Ratings
This is a breakdown of current recommendations for LadRx and Quince Therapeutics, as provided by MarketBeat.com.
Get LadRx alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
LadRx | 0 | 0 | 0 | 0 | N/A |
Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares LadRx and Quince Therapeutics' top-line revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
Quince Therapeutics | N/A | N/A | -$89.94 million | ($2.23) | -0.31 |
Quince Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Profitability
This table compares LadRx and Quince Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
LadRx | N/A | -67.61% | -45.39% |
Quince Therapeutics | N/A | -63.19% | -58.43% |
Insider and Institutional Ownership
0.1% of LadRx shares are held by institutional investors. Comparatively, 25.8% of Quince Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 27.9% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
About LadRx
(Get Rating)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
About Quince Therapeutics
(Get Rating)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
LadRx (OTCMKTS:CYTR – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.
LadrX(OTCMKTS: CYTR — 获取评级)和Quince Therapeutics(纳斯达克股票代码:QNCX — Get Ratings)都是小型医疗公司,但哪一项是更优的投资?我们将根据两家企业的机构所有权、股息、风险、收益、盈利能力、分析师建议和估值来比较这两家企业。
Analyst Ratings
分析师评级
This is a breakdown of current recommendations for LadRx and Quince Therapeutics, as provided by MarketBeat.com.
这是Marketbeat.com提供的LadrX和Quince Therapeutics目前推荐的明细。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
LadRx | 0 | 0 | 0 | 0 | N/A |
Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
LadRx | 0 | 0 | 0 | 0 | 不适用 |
昆斯疗法 | 0 | 0 | 0 | 0 | 不适用 |
Earnings & Valuation
收益与估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
Quince Therapeutics | N/A | N/A | -$89.94 million | ($2.23) | -0.31 |
总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
LadRx | 不适用 | 不适用 | -670 万美元 | (0.15 美元) | 不适用 |
昆斯疗法 | 不适用 | 不适用 | -8994 万美元 | (2.23 美元) | -0.31 |
Quince Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
Quince Therapeutics的市盈率低于LadRx,这表明它是目前这两只股票中更实惠的一只。
Volatility & Risk
波动性与风险
LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
LadRx的beta值为1.96,这表明其股价的波动性比标准普尔500指数高96%。相比之下,Quince Therapeutics的beta值为1.08,这表明其股价的波动性比标准普尔500指数高8%。
Profitability
盈利能力
This table compares LadRx and Quince Therapeutics' net margins, return on equity and return on assets.
该表比较了LadRx和Quince Therapeutics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
LadRx | N/A | -67.61% | -45.39% |
Quince Therapeutics | N/A | -63.19% | -58.43% |
净利润 | 股本回报率 | 资产回报率 | |
LadRx | 不适用 | -67.61% | -45.39% |
昆斯疗法 | 不适用 | -63.19% | -58.43% |
Insider and Institutional Ownership
内部所有权和机构所有权
0.1% of LadRx shares are held by institutional investors. Comparatively, 25.8% of Quince Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 27.9% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
0.1%的LadRx股票由机构投资者持有。相比之下,25.8%的Quince Therapeutics股票由机构投资者持有。12.8%的LadRx股票由内部人士持有。相比之下,27.9%的Quince Therapeutics股份由内部人士持有。强大的机构所有权表明,大型基金经理、对冲基金和捐赠基金认为,从长远来看,股票的表现将超过市场。
About LadRx
关于 LadRx
(Get Rating)
(获取评分)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx Corporation是一家生物制药公司,从事治疗癌症患者的疗法的发现和开发。该公司的先进药物偶联物阿多柔比星正在进行后期临床试验,是抗癌药物多柔比星的一种版本。其临床前疗法包括针对癌症的链接活化药物释放的7、8、9和10。该公司前身为CytrX Corporation,并于2022年9月更名为LadrX Corporation。LadRx Corporation 成立于 1985 年,总部位于加利福尼亚州洛杉矶。
About Quince Therapeutics
关于昆斯疗法
(Get Rating)
(获取评分)
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. 是一家生物制药公司,专注于推动针对使人衰弱和罕见疾病的精准疗法。该公司发现了一个广泛的骨靶向药物平台,可以将小分子、肽或大分子精确地直接输送到骨折和疾病部位。其主要化合物是 NOV004,这是一种合成代谢肽,专为精确靶向和浓缩骨折部位而设计。该公司前身为 Cortexyme, Inc.,并于 2022 年 8 月更名为 Quince Therapeutics, Inc.Quince Therapeutics, Inc. 成立于2012年,总部位于加利福尼亚州南旧金山。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 LadRx 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收LadrX及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧